Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Expanded Program on Immunization


Background and Definition
Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in  700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.
 
EPI ِAims at:
  1. Elevating routine vaccination coverage per district to above 95%.
  2. Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
  3. Eradicating Measles and Rubella by the end of year 2018.
 
EPI Activities:
  1. Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
  2. Continuous work to keep Lebanon certified polio-free
  3. Implementation of the RED STRATEGY to reach every child, which includes:
    1. Data on the immunization coverage for children under one year of age
    2. Data on immunization coverage in Lebanon
    3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
  4. Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination 
  5. Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
  6. Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service 
  7. Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
  8. Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.
     
    3
ATC Name B/G Ingredients Dosage Form Price
A10BD08 GALVUS MET B Metformin HCl - 1,000mg, Vildagliptin - 50mg Tablet, film coated 1,816,875 L.L
A10BA02 GLUCOPHAGE B Metformin HCl - 1,000mg 1,000mg Tablet, film coated 624,963 L.L
A10BA02 GLUCOBAS G Metformin - 850mg 850mg Tablet 217,575 L.L
A10BA02 GLUCOBAS G Metformin - 1000mg 1000mg Tablet 302,045 L.L
P03AB02 GAMMA BENZENE HEXACHLORIDE G Lindane - 1% 1% Shampoo 195,817 L.L
P03AB02 GAMMAPHARM G Lindane - 1% 1% Shampoo 195,817 L.L
P03AB02 GAMMA BENZENE HEXACHLORIDE G Lindane - 1% 1% Lotion 167,660 L.L
A10BD19 GLYXAMBI B Linagliptin - 5mg, Empagliflozin - 25mg Tablet, film coated 4,482,387 L.L
A10BD19 GLYXAMBI B Linagliptin - 5mg, Empagliflozin - 25mg Tablet, film coated 4,482,387 L.L
A10BD19 GLYXAMBI B Linagliptin - 5mg, Empagliflozin - 10mg Tablet, film coated 4,482,387 L.L
A10BD19 GLYXAMBI B Linagliptin - 5mg, Empagliflozin - 10mg Tablet, film coated 4,482,387 L.L
A03FA07 GANATON B Itopride Hydrochloride - 50mg 50mg Tablet 1,119,421 L.L
A03FA07 GANATON B Itopride Hydrochloride - 50mg 50mg Tablet 357,462 L.L
A03FA07 GAROPRIDE G Itopride Hydrochloride - 50mg 50mg Tablet, film coated 213,671 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 25mg Tablet, film coated 768,678 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C09CA04 GIZLAN G Irbesartan - 300mg 300mg Tablet, film coated 768,678 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C09CA04 GIZLAN G Irbesartan - 150mg 150mg Tablet, film coated 748,520 L.L
A10AE04 GLARTUS BioTech Insulin glargine - 100U/ml 100U/ml Injectable solution 1,346,530 L.L
D06BB10 GENIMOD G Imiquimod - 5% 5% Cream 2,268,406 L.L
L01EA01 GLIMATINIB BENTA 400 G Imatinib (mesylate) - 400mg 400mg Tablet, film coated 38,254,090 L.L
L01EA01 GLIVEC B Imatinib (mesylate) - 100mg 100mg Tablet, film coated 50,531,993 L.L
L01EA01 GLIMATINIB BENTA G Imatinib (mesylate) - 100mg 100mg Tablet, film coated 17,619,185 L.L
L01EA01 GLIMATINIB BENTA G Imatinib (mesylate) - 100mg 100mg Tablet, film coated 43,103,200 L.L
J06BA02 GAMUNEX-C BioHuman Human normal immunoglobulin G - 10% 10% Injectable solution 39,990,287 L.L
C05CA54 GINKOR FORT B Heptaminol HCl - 0.300g, Troxerutine - 0.300g, Ginkgo biloba extract - 0.014g Capsule 681,328 L.L
D01BA01 GRISEOFULVIN G Griseofulvin - 500mg 500mg Tablet, scored 575,933 L.L
A04AA02 GRANI-DENK G Granisetron - 3mg/3ml 3mg/3ml Injectable concentrate for solution 1,679,803 L.L
A04AA02 GRANI-DENK G Granisetron - 1mg/ml 1mg/ml Injectable concentrate for solution 893,655 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2025